ATE438614T1 - N-alkoxyalkyl-n,n-dialkylamin-derivate oder ihre salze und heilmittel zur behandlung degenerativer erkrankungen der nerven die diese enthalten - Google Patents

N-alkoxyalkyl-n,n-dialkylamin-derivate oder ihre salze und heilmittel zur behandlung degenerativer erkrankungen der nerven die diese enthalten

Info

Publication number
ATE438614T1
ATE438614T1 AT00935600T AT00935600T ATE438614T1 AT E438614 T1 ATE438614 T1 AT E438614T1 AT 00935600 T AT00935600 T AT 00935600T AT 00935600 T AT00935600 T AT 00935600T AT E438614 T1 ATE438614 T1 AT E438614T1
Authority
AT
Austria
Prior art keywords
alkoxyalkyl
treatment
dialkylamin
remedies
nerves
Prior art date
Application number
AT00935600T
Other languages
English (en)
Inventor
Satoshi Ono
Akihito Saito
Noboru Iwakami
Masaya Nakagawa
Sumie Yamaguchi
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Application granted granted Critical
Publication of ATE438614T1 publication Critical patent/ATE438614T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C07C217/10—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT00935600T 1999-06-11 2000-06-09 N-alkoxyalkyl-n,n-dialkylamin-derivate oder ihre salze und heilmittel zur behandlung degenerativer erkrankungen der nerven die diese enthalten ATE438614T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP16587999 1999-06-11
PCT/JP2000/003748 WO2000076957A1 (en) 1999-06-11 2000-06-09 N-alkoxyalkyl-n,n-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same

Publications (1)

Publication Number Publication Date
ATE438614T1 true ATE438614T1 (de) 2009-08-15

Family

ID=15820725

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00935600T ATE438614T1 (de) 1999-06-11 2000-06-09 N-alkoxyalkyl-n,n-dialkylamin-derivate oder ihre salze und heilmittel zur behandlung degenerativer erkrankungen der nerven die diese enthalten

Country Status (24)

Country Link
US (1) US6797726B1 (de)
EP (1) EP1186594B1 (de)
JP (1) JP4782961B2 (de)
KR (1) KR100641352B1 (de)
CN (1) CN1155558C (de)
AT (1) ATE438614T1 (de)
AU (1) AU770234B2 (de)
BR (1) BR0011505A (de)
CA (1) CA2374659C (de)
CY (1) CY1109334T1 (de)
CZ (1) CZ302083B6 (de)
DE (1) DE60042686D1 (de)
DK (1) DK1186594T3 (de)
ES (1) ES2329003T3 (de)
HU (1) HU229250B1 (de)
MX (1) MXPA01012627A (de)
NO (1) NO322473B1 (de)
NZ (1) NZ515706A (de)
PL (1) PL196773B1 (de)
PT (1) PT1186594E (de)
RO (1) RO122361B1 (de)
SK (1) SK287673B6 (de)
WO (1) WO2000076957A1 (de)
ZA (1) ZA200109699B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2464358C (en) 2001-10-19 2011-05-24 Toyama Chemical Co., Ltd. Alkyl ether derivatives or their salts
KR100935615B1 (ko) * 2002-06-14 2010-01-07 토야마 케미칼 컴퍼니 리미티드 뇌기능을 개선하는 의약조성물 및 뇌기능을 개선하기 위한방법
RU2225867C1 (ru) * 2002-11-18 2004-03-20 Катаев Валерий Алексеевич 1-(1,1-диоксотиетанил-3)-2-морфолинобензимидазола гидрохлорид, повышающий устойчивость к острой гипоксии с гиперкапнией
EP1707203A1 (de) * 2005-04-01 2006-10-04 Bioprojet Verwendung von Alkylaminen, die kein Imidazole enthalten, als Histamin H3 Rezeptor Liganden, zur Behandlung von Morbus Parkinson, obstruktiver Schlafapnoe, vaskularer Demenz, Demenz mit Lewy Korpen
JP4902247B2 (ja) * 2005-04-08 2012-03-21 富山化学工業株式会社 ２−（１−ベンゾチオフェン−５−イル）エタノールの新規製造法およびその中間体
JP2006328058A (ja) * 2005-04-27 2006-12-07 Toyama Chem Co Ltd ２−（１−ベンゾチオフェン−５−イル）エタノールの新規製造法およびその中間体
ES2518371T3 (es) * 2006-04-26 2014-11-05 Toyama Chemical Co., Ltd. Inductor de la neurogénesis o agente terapéutico para la neuropatía que comprende un derivado de éter alquílico o una sal del mismo
US8119625B2 (en) * 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
FR2933977B1 (fr) * 2008-07-18 2013-04-26 Centre Nat Rech Scient Derives heterocycliques utiles dans le traitement des maladies neurodegeneratives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2820817A (en) * 1954-02-04 1958-01-21 Mcneilab Inc Oxygenated indan compounds and method of making the same
US5280032A (en) 1989-02-14 1994-01-18 Toyama Chemical Co., Ltd. 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same
JP2887492B2 (ja) * 1990-02-05 1999-04-26 富山化学工業株式会社 １，２―エタンジオール誘導体およびその塩
JP3044055B2 (ja) * 1990-08-09 2000-05-22 富山化学工業株式会社 １，２―エタンジオール誘導体およびその塩
JP2873898B2 (ja) * 1992-04-13 1999-03-24 富山化学工業株式会社 ベンゾ［ｂ］チオフェン−５−イル誘導体もしくはその光学活性体またはそれらの塩並びにそれらの製造法
WO1995019336A1 (de) * 1994-01-12 1995-07-20 Iovis Biomedical And Pharmaceutical Consultants Phenylethanolaminether und ihre verwendung als beta-adrenorezeptor-agonisten
DK0790246T3 (da) 1994-10-25 2002-03-18 Toyama Chemical Co Ltd Middel til potensering af nervevækstfaktoraktivitet indeholdende 1,2-ethandiolderivat eller salt deraf
WO1999031056A1 (en) * 1997-12-12 1999-06-24 Toyama Chemical Co., Ltd. Alkyl ether derivatives or salts thereof and calcium antagonists containing the same

Also Published As

Publication number Publication date
DE60042686D1 (de) 2009-09-17
CY1109334T1 (el) 2014-07-02
HUP0204177A2 (hu) 2003-03-28
AU770234B2 (en) 2004-02-19
AU5107200A (en) 2001-01-02
PT1186594E (pt) 2009-10-13
BR0011505A (pt) 2002-08-20
EP1186594A1 (de) 2002-03-13
CZ302083B6 (cs) 2010-09-29
EP1186594B1 (de) 2009-08-05
DK1186594T3 (da) 2009-09-14
ES2329003T3 (es) 2009-11-20
HUP0204177A3 (en) 2007-05-29
MXPA01012627A (es) 2003-09-04
PL196773B1 (pl) 2008-01-31
NO20016029L (no) 2001-12-10
ZA200109699B (en) 2003-03-12
CN1358169A (zh) 2002-07-10
EP1186594A4 (de) 2006-01-11
NZ515706A (en) 2003-08-29
SK287673B6 (sk) 2011-05-06
CA2374659C (en) 2010-07-13
NO20016029D0 (no) 2001-12-10
KR20020013902A (ko) 2002-02-21
KR100641352B1 (ko) 2006-11-02
SK17812001A3 (sk) 2002-11-06
US6797726B1 (en) 2004-09-28
RO122361B1 (ro) 2009-04-30
CN1155558C (zh) 2004-06-30
WO2000076957A1 (en) 2000-12-21
PL352172A1 (en) 2003-07-28
HU229250B1 (en) 2013-10-28
NO322473B1 (no) 2006-10-09
CA2374659A1 (en) 2000-12-21
JP4782961B2 (ja) 2011-09-28

Similar Documents

Publication Publication Date Title
AU692090B2 (en) Novel 4,6-diarylpyrimidine derivatives and salts thereof
EE03139B1 (et) Piperasiiniderivaadid, nende kasutamine ja farmatseutiline kompositsioon
EA200100487A1 (ru) Производные 2-аминотиазола, способ их получения и применение указанных веществ в качестве противоопухолевых средств
ATE255091T1 (de) 1-acetyl-5-bromo-4,6-dimethylindolin
ATE218573T1 (de) Substituierte 4-arylmethylene-2-imino-2,3- dihydrothiazolen, ihre derivaten, und ihre pharmazeutische verwendung
LV12457A (lv) Acil-piperazinil-pirimidinu atvasinajumi to iegusana un izmantosana par medikamentiem
DE69316067D1 (de) Arzneimittel zur Verwendung bei der Behandlung von Parkinsonismus
DE60042686D1 (de) N-alkoxyalkyl-n,n-dialkylamin-derivate oder ihre salze und heilmittel zur behandlung degenerativer erkrankungen der nerven die diese enthalten
ATE359267T1 (de) Azaheterozyklischederivate zur behandlung von haarausfall und neurologischer krankheiten
ES2099206T3 (es) Derivados de benceno que favorecen la produccion del factor de crecimiento de los nervios humanos.
BR0010134A (pt) Uso de derivados de ácido 2,4-diamino-3-hidroxicarboxìlico como inibidores de proteassoma
DE69427587D1 (de) Cyclohexandiharnstoff-derivate und verfahren zu deren herstellung
ATE114154T1 (de) Thienotriazolodiazepine und ihre pharmazeutische verwendung.
DE69530516D1 (de) Pyrimidin-derivate
DE3774273D1 (de) Chinazolin-derivat, verfahren zu dessen herstellung und mittel zur behandlung von cerebraler disfunktion als aktiver inhaltsstoff.
ATE425967T1 (de) Piperazin und piperadin-derivate fur die behandlung von neurologischen krankheiten
ATE209633T1 (de) Pyridinderivate,als arzneimittel zur behandlung von geschwüren und als antibakterielle mittel
DE69827706D1 (de) 5-(Heteroaryl)alkyl)-3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid (PBI) Derivate zur Behandlung von Störungen des zentralen Nervensystems
RU94045291A (ru) Соединения полезные при лечения аллергических и воспалительных заболеваний, композиция, способ лечения

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1186594

Country of ref document: EP